Trial
NCT04635059
Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Medical College of Wisconsin
Collaborators
—
Condition
Prostate Cancer
Intervention
Pacritinib
Why stopped
futility and drug supplier in favor of new metastatic protocol.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-17